KPF
AVIR icon

K2 Principal Fund’s Atea Pharmaceuticals AVIR Stock Holding History

K2 Principal Fund’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-605,419
Closed -$3.44M – 253
2022
Q3 		$3.44M Sell
605,419
-1,000,640
-62% -$7.66M 0.4% 68
2022
Q2 		$11.4M Buy
+1,606,059
New +$11M 1.26% 14

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

K2 Principal Fund's AVIR Position: Q4 2022 in Review

K2 Principal Fund sold out of Atea Pharmaceuticals (AVIR) in Q4 2022, closing a stake of 605,419 shares — an estimated $3.44M sold.

K2 Principal Fund first reported a position in AVIR in Q2 2022 and held it in 2 quarters. The position peaked at $11.4M in Q2 2022. 131 funds tracked by Wall St. Rank hold AVIR as of Q4 2022.

  • K2 Principal Fund reported no remaining Atea Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • K2 Principal Fund sold 605,419 Atea Pharmaceuticals shares in Q4 2022, an estimated $3.44M.
  • K2 Principal Fund first reported a position in Atea Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • K2 Principal Fund's Atea Pharmaceuticals position peaked at $11.4M in Q2 2022.
  • 131 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2022.

Based on K2 Principal Fund's 13F filing for Q4 2022, filed 10 Feb 2023.